Epilepsy in 2017

Precision medicine drives epilepsy classification and therapy

2017 saw the publication of new classifications for epilepsy and seizure types, which emphasize the importance of understanding the underlying disease mechanisms. This aetiology-based approach is already beginning to inform developments in therapies and trial design in the epilepsies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 512–521 (2017).

    Article  Google Scholar 

  2. 2

    Fisher, R. S. et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia 58, 522–530 (2017).

    Article  Google Scholar 

  3. 3

    Fisher, R. S. et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58, 531–542 (2017).

    Article  Google Scholar 

  4. 4

    [No authors listed]. Proposal for revised classification for epilepsies and epileptic syndromes. Epilepsia 30, 389–399 (1989).

  5. 5

    Devinsky, O. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label intervention trial. Lancet Neurol. 15, 270–278 (2016).

    CAS  Article  Google Scholar 

  6. 6

    Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med. 376, 2011–2020 (2017).

    CAS  Article  Google Scholar 

  7. 7

    Wu, Y. W. et al. Incidence of Dravet syndrome in a US population. Pediatrics 136, e1310–e1315 (2015).

    Article  Google Scholar 

  8. 8

    Dwivedi, R. et al. Surgery for drug-resistant epilepsy in children. N. Engl. J. Med. 377, 1639–1647 (2017).

    Article  Google Scholar 

  9. 9

    Kim, D. W. et al. Surgical treatment of non-lesional neocortical epilepsy: long-term longitudinal study. JAMA Neurol, 74, 324–331 (2017).

    Article  Google Scholar 

  10. 10

    O'Callaghan, F. J. et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 16, 33–42 (2017).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Sameer M. Zuberi.

Ethics declarations

Competing interests

S.M.Z. has received honoraria for educational activities and advisory boards from GW Pharma, paid to his institution's charitable account. He was Chair of the International League Against Epilepsy Commission for Classification and Terminology from 2013–2017. A.B. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zuberi, S., Brunklaus, A. Precision medicine drives epilepsy classification and therapy. Nat Rev Neurol 14, 67–68 (2018). https://doi.org/10.1038/nrneurol.2017.190

Download citation

Further reading


Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing